We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Debiopharm Group™ Presents The ‘JCA Mauvernay Award 2013’


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Debiopharm Group™ Presents The ‘JCA Mauvernay Award 2013’"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Debiopharm Group™ (Debiopharm) will be presenting the ‘JCA-Mauvernay Award’ on October 5, to Doctors Issay Kitabayashi from Tokyo National Cancer Center Research Institute for his basic research on ‘Molecular study of acute myeloid leukemia and its application for therapy’ and Seiji Yano from Kanazawa University for his applied research on ‘Circumvention of molecular targeted drug resistance in lung cancer’.

Doctors Kitabayashi and Yano will receive their Awards during the General Assembly of the 72nd Annual Conference of the Japanese Cancer Association (JCA) in Yokohama on the following theme: ‘Cancer research providing hope to fight against cancer’.

Dr. Tetsuo Noda, President of the JCA and a Debiopharm Group representative will present the trophies to both scientists.

“The selecting committee members chose the nominees for the high standard and application possibilities of their research. Debiopharm is honored to be part of this Award with the JCA and wishes both scientists success with their work,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

Dr Kitabayashi focuses on the molecular study of the basis of the development of acute myeloid leukemia (AML). He shows that it is related to chromosomal rearrangements modifying the function of genes involved in transcription and hematopoiesis (AML1, PML, MOZ).

Molecular drugs like EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors (TKIs) show dramatic effects in lung cancer patients. However resistance to EGFR-TKIs is a major problem in current clinical practice.

Dr Yano aims to conduct clinical trials to elucidate and overcome the molecular mechanisms involved in the resistance to lung cancer drugs and to establish treatments to overcome it.

Advertisement